Icon

OPSYNVI (NDA218490)- (10MG;20MG,10MG;40MG)

MACITENTAN; TADALAFIL ACTELION
10MG;20MG,10MG;40MG
No Yes
2029-Apr-18 Expired
None 2027-Mar-22
None No
OPSYNVI is a combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, indicated for chronic treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients of WHO functional class (FC) II-III. Individually, macitentan reduces the risk of clinical worsening events and hospitalization, and tadalafil improves exercise ability.
0 0 0
Total Other Developers None
Drugs with Suitability No
10MG;20MG ** ** - - -
10MG;40MG ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.